BUN

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
화요일, 5월 14, 2024
Hypersensitivity, New Drug Application, Patient, Creatinine, Ototoxicity, Uric acid, Azotemia, Huber loss, Coma, Anuria, Cerebral edema, Urinary retention, Erythema, NYHA, Furosemide, Heart failure, Ascites, Hepatic encephalopathy, Kidney, Bruise, Shanda, Urine, FDA, Glucose, Trial of the century, GTN, Edema, PDUFA, Chronic kidney disease, Cirrhosis, Change Healthcare, Growth, Research, Diuresis, BUN, Dehydration, Thrombosis, Deafness, Congestion, CO2, Oliguria, Benign prostatic hyperplasia, Organic acid, History, Blood volume, Hypoproteinemia, Embolism, Tinnitus, Pharmaceutical industry

BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million for the first quarter of 2024, compared to $2.1 million for the first quarter of 2023.
  • Costs of product revenues were $1.8 million for the first quarter of 2024, compared to $0.6 million for the first quarter of 2023.
  • Research and development expenses were $2.7 million for the first quarter of 2024, compared to $2.1 million for the first quarter of 2023.
  • scPharmaceuticals reported a net loss of $14.1 million for the first quarter of 2024, compared to $11.2 million for the first quarter of 2023.

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Retrieved on: 
수요일, 4월 24, 2024
Urine, Kidney, FDA, Shanda, Embolism, Huber loss, Hepatic encephalopathy, Uric acid, Oliguria, Congestion, Blood volume, Furosemide, Organic acid, Deafness, Erythema, Cerebral edema, Ascites, Tinnitus, History, Thrombosis, Creatinine, NYHA, Dehydration, BUN, Patient, Hypersensitivity, Ototoxicity, Anuria, Glucose, Azotemia, Hypoproteinemia, CO2, Diuresis, Cirrhosis, Chronic kidney disease, Edema, Urinary retention, Bruise, Growth, Benign prostatic hyperplasia, Coma, Heart failure, Pharmaceutical industry

BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

Key Points: 
  • The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility.
  • If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
수요일, 3월 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

What do your blood test results mean? A toxicologist explains the basics of how to interpret them

Retrieved on: 
화요일, 2월 6, 2024
Glycated hemoglobin, Thyroid, BMP, Physical examination, Disorder, Hypothyroidism, Cell, BUN, Immune system, History, RBC, Heart, Blood urea nitrogen, Diabetes, Biomarker, Blood, Patient, Kidney, Triiodothyronine, Temperature, HB, TSH, Anemia, Nutrient, A1C, Disease, Thyroid hormones, Brain, Hematocrit, Fatigue, Waste, Health, HCT, Hormone, Plasma, Woman, Medical imaging

As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.

Key Points: 
  • As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.
  • Understanding what common blood tests are intended to measure can help you better interpret the results.
  • If you have results from a recent blood test handy, please follow along.

Normal blood test ranges

  • This range is essentially the upper and lower limits within which most healthy people’s test results are expected to fall.
  • To determine how your test results compare with the normal range, you need to check the reference interval listed on your lab report.
  • If you have results for a given test from different labs, your clinician will likely focus on test trends relative to their reference intervals and not the numerical results themselves.

Interpreting your blood test results

  • There are numerous blood panels intended to test specific aspects of your health.
  • These include panels that look at the cellular components of your blood, biomarkers of kidney and liver function, and many more.
  • This results from either lower than normal levels of red blood cells or a decrease in the quantity or quality of hemoglobin, the protein that allows these cells to transport oxygen.
  • A complete blood count panel measures various components of the blood to provide a comprehensive overview of the cells that make it up.
  • Low values of red blood cell count, or RBC, hemoglobin, or Hb, and hematocrit, or HCT, would indicate that the patient is suffering from anemia.
  • Providing additional information is the basic metabolic panel, or BMP, which measures the amount various substances in your blood.


With results from each of these panels, the health professional would assess the patient’s values relative to their reference intervals and determine which condition they most likely have. Understanding the purpose of blood tests and how to interpret them can help patients partner with their health care providers and become more informed about their health.
Brad Reisfeld does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
목요일, 1월 4, 2024
Coma, Urine, Hepatic encephalopathy, Ascites, Kidney, Oliguria, Physician, Benign prostatic hyperplasia, Blood volume, Uric acid, Organic acid, Anuria, Urinary retention, NYHA, Furosemide, Cerebral edema, Hypersensitivity, Diuresis, Thrombosis, Deafness, Glucose, Azotemia, Ototoxicity, Creatinine, Tinnitus, Traction, BUN, Hypoproteinemia, Edema, Growth, Investment, Congestion, Huber loss, Patient, Bruise, Dehydration, CO2, Heart failure, Cirrhosis, Embolism, History, Erythema, Pharmaceutical industry

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
수요일, 11월 8, 2023
NYHA, Cirrhosis, FDA, Research, Uric acid, Trial of the century, Deafness, Furosemide, Thrombosis, Erythema, Benign prostatic hyperplasia, Embolism, Internationalized domain name, Government, Hypoproteinemia, History, Kidney, Physician, Cerebral edema, Anuria, Bruise, Edema, Hepatic encephalopathy, Huber loss, Ototoxicity, Chronic kidney disease, Urinary retention, Congestion, Blood volume, Growth, Urine, Dehydration, Shanda, Diuresis, Pharmacy, Tinnitus, Medicaid, Azotemia, BUN, CO2, Oliguria, Organic acid, CKD, Investment, Patient, Creatinine, Heart failure, Hypersensitivity, Glucose, Coma, New York Heart Association Functional Classification, Ascites, Security (finance), Cryptocurrency, Pharmaceutical industry, Rare-earth element, Health insurance, Medical device, Video game, BURLINGTON

BURLINGTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $3.8 million, and cost of product revenues were $1.1 million for the third quarter of 2023.
  • Research and development expenses were $3.4 million for the third quarter of 2023, compared to $3.7 million for the third quarter of 2022.
  • Selling, general and administrative expenses were $14.1 million for the third quarter of 2023, compared to $6.3 million for the third quarter of 2022.
  • As of September 30, 2023, scPharmaceuticals’ total shares outstanding was 35,859,045.
    scPharmaceuticals’ management will host a conference call and webcast to review the Company’s third quarter 2023 results today, Wednesday, November 8, at 4:30 p.m.

CLEARSTEM Skincare Introduces Its First Ever Acne Lab Test

Retrieved on: 
화요일, 10월 3, 2023
Blood urea nitrogen, Acne, Research, CEA-LIST: Laboratory for Integration of Systems and Technology, SAN, CGO, Nutrition, MCV, BUN, Skin, Cosmetics, Sulfur, Creatinine

SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- CLEARSTEM Skincare (CLEARSTEM), the non-toxic, clean skincare brand, announced its telehealth debut with the launch of its CLEARSTEM Acne Lab Test. CLEARSTEM's revolutionary Acne Lab Test introduces a new era of skincare designed to identify consumer's unique root cause(s) of acne and provide a personalized treatment plan. The blood test is currently sold online clearstemskincare.com.

Key Points: 
  • SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- CLEARSTEM Skincare (CLEARSTEM), the non-toxic, clean skincare brand, announced its telehealth debut with the launch of its CLEARSTEM Acne Lab Test .
  • CLEARSTEM's revolutionary Acne Lab Test introduces a new era of skincare designed to identify consumer's unique root cause(s) of acne and provide a personalized treatment plan.
  • "After years of research we are beyond excited for people to find their exact root cause of acne through our Acne Lab Test and relieve themselves of the constant frustration and mental toll that struggling with acne takes."
  • The CLEARSTEM Acne Lab Test is sold exclusively at clearstemskincare.com for $449, which includes lab tests, personal root cause of acne report, analysis, protocol, blood draw, and three free months of access to membership program.

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Retrieved on: 
화요일, 9월 19, 2023
Overload, Furosemide, PK, Hypersensitivity, NYHA, Congestion, Embolism, Hypoproteinemia, Organic acid, Heart failure, Hospital, Urine, Creatinine, Cirrhosis, Dehydration, Glucose, Tinnitus, Deafness, Huber loss, Edema, Hepatic encephalopathy, Oliguria, History, Solubility, Type, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Shanda, Investigational New Drug, HIV disease progression rates, Patent, Patient, Physician, Ototoxicity, Urinary retention, Erythema, Azotemia, Ascites, Coma, Type D, Growth, Diagnosis, Blood volume, FDA, Benign prostatic hyperplasia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CKD, Cerebral edema, CO2, Thrombosis, BUN, Food, Kidney disease, Anuria, Pharmaceutical industry

BURLINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the Company has received positive feedback from the U.S. Food and Drug Administration (FDA) on two key long-term growth initiatives.

Key Points: 
  • The Company also announced today feedback from a Type D meeting with the FDA pertaining to the potential expansion of the FUROSCIX label to include treatment of edema due to fluid overload in patients with CKD.
  • In its feedback, the FDA confirmed that no additional clinical studies are needed to expand the indication, provided that the Company demonstrates an adequate PK and pharmacodynamic bridge to the listed drug, furosemide injection, 10 mg/mL.
  • CKD is a progressive disease characterized by worsening renal function over time, resulting in frequent episodes of fluid overload that are treated with loop diuretics.
  • “We are very pleased to have reached alignment with the FDA on the advancement of these two very important long-term growth initiatives for our company,” stated John Tucker, Chief Executive Officer of scPharmaceuticals.

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
목요일, 8월 10, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, Medicaid, Hypoproteinemia, Organic acid, Heart failure, Urine, Creatinine, Patient satisfaction, Cirrhosis, Dehydration, Tinnitus, Glucose, Deafness, Huber loss, Edema, Hepatic encephalopathy, Prescription, Research, Part, Oliguria, History, Government, Russell 3000 Index, Trial of the century, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Investment, Patient, Russell, Urinary retention, Cardiology, Azotemia, Ascites, Coma, Blood volume, FDA, Benign prostatic hyperplasia, Thrombosis, IND, Cerebral edema, CO2, BUN, Anuria, Security (finance), Cryptocurrency, Pharmaceutical industry, Health insurance, Medical device, Video game, BURLINGTON

BURLINGTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2023, and provided a business update. 

Key Points: 
  • For the second quarter ended June 30, 2023, scPharmaceuticals reports:
    Obtained national Medicaid coverage of FUROSCIX effective July 1, 2023.
  • Ended the second quarter of 2023 with cash, cash equivalents and short-term investments of $102.9 million.
  • Research and development expenses were $2.9 million for the second quarter of 2023, compared to $5.1 million for the second quarter of 2022.
  • Selling, general and administrative expenses were $12.1 million for the second quarter of 2023, compared to $4.3 million for the second quarter of 2022.

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

Retrieved on: 
화요일, 8월 1, 2023
Hypersensitivity, Furosemide, NYHA, Congestion, Embolism, US Foods, Hypoproteinemia, Organic acid, Heart failure, Chronic kidney disease, Urine, Creatinine, Cirrhosis, Dehydration, Glucose, Tinnitus, Deafness, Huber loss, Edema, Hepatic encephalopathy, Oliguria, History, Solubility, Diuresis, Uric acid, New York Heart Association Functional Classification, Kidney, Bruise, Ototoxicity, Erythema, Patent, Patient, Physician, Urinary retention, Azotemia, Ascites, Coma, Blood volume, FDA, Benign prostatic hyperplasia, Thrombosis, IND, Cerebral edema, CO2, BUN, Kidney disease, Anuria, Pharmaceutical industry, Medical device

FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure.

Key Points: 
  • FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure.
  • “We are very pleased with the outcome of our recent Type C meeting with the FDA, and believe this paves the way for potential expansion of the FUROSCIX indication to allow for use in NYHA Class IV patients,” stated John Tucker, Chief Executive Officer of scPharmaceuticals.
  • “We estimate that as many as 10% of all heart failure patients are Class IV, and a meaningful percentage of these – as many as 40% - may benefit from FUROSCIX.
  • FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.